1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Joffe, E.; Nowakowski, G. S.; Tun, H. W.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Li, C. C.; Zhou, L.; Martinez, E.; Von Roemeling, R. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers
    Meeting Abstract

    Johnson, M. L.; Dy, G. K.; Mamdani, H.; Dowlati, A.; Schoenfeld, A. J.; Pacheco, J. M.; Sanborn, R. E.; Menon, S. P.; Santiago, L.; Yaron, Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1
    Meeting Abstract

    Jakubowiak, A. J.; Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Byrne, J.; Eliason, L.; Scott, E. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Estimating clear cell renal cell carcinoma transcriptomic signatures using machine learning and histopathology images
    Meeting Abstract

    Hassanpour, S.; Tomita, N.; Kotecha, R.; Lee, C. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of a shared-care model between community and academic centers for facilitating access to allogeneic and autologous stem cell transplantation
    Meeting Abstract

    Fein, J. A.; McAuliffe, A.; Fischer, K.; Brady, O.; Devlin, S. M.; Willumsen, S.; Ozcan, G.; Montanaro, P.; Pristyazhnyuk, Y.; Digiuseppe, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Disparities in speed to BMT consult and allograft in 279 adults with AML
    Meeting Abstract

    Fingrut, W. B.; Gyurkocza, B.; Davis, E.; Flynn, J.; Scaradavou, A.; Chinapen, S.; Naputo, K.; Quach, S.; Cho, C.; Giralt, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save